Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 19/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29895625 | 1.00 | PTGES (0.47) | PTGESPTGS2HDAC4 | |
| SCHEMBL26225689 | 0.93 | PTGES (0.46) | PTGESPTGS2HDAC4 | |
| SCHEMBL29630913 | 0.90 | PTGES (0.50) | PTGESPTGS2 | |
| SCHEMBL29630854 | 0.90 | PTGES (0.46) | PTGESPTGS2HDAC4 | |
| SCHEMBL26225711 | 0.90 | PTGES (0.46) | PTGESPTGS2HDAC4 | |
| SCHEMBL26225779 | 0.90 | PTGES (0.50) | PTGESPTGS2 | |
| SCHEMBL26225713 | 0.90 | PTGES (0.50) | PTGESPTGS2 | |
| SCHEMBL29630851 | 0.88 | PTGES (0.44) | PTGESPTGS2HDAC4 | |
| SCHEMBL26225694 | 0.88 | PTGES (0.44) | PTGESPTGS2HDAC4 | |
| SCHEMBL24473774 | 0.87 | PTGES (0.54) | PTGESPTGS2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286968-A1 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286968-A1 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286968-A1 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP4B1, CYP1B1 | PTGES 1456/4885PTGS2 1411/4885HDAC4 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.